

Investor Presentation

Q1FY27

23-07-2026

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

Delivered the Highest Q1 Revenue




	Revenue	EBITDA	PAT
Q1FY27	INR 7,119 Cr	INR 1,192 Cr ⎓ 16.7% Margin	INR 789 Cr ⎓ 11.1% Margin

Business Performance Snapshot

	One India	North America	One Africa	Emerging Markets & Europe
Q1FY27	INR 3,452 Cr ⬆ 12% (YoY)	\$ 162 Mn	\$ 103 Mn ⬆ 1% (YoY)	\$ 106 Mn ⬆ 5% (YoY)
	Highest-ever quarterly revenue	Launched first AB-rated gVentolin with CGT	SA private growing faster than the market ¹	Continued growth trajectory

1. Market data as per IQVIA MAT May'26

Revenues INR 7,119 Cr



EBITDA 1,192 Cr

Q1FY27 (Consolidated)		
	Q1FY27 (INR Cr)	Q1FY26 (INR Cr)
Total Revenue from Operations	7,119	6,957
EBITDA	1,192	1,778
EBITDA %	16.7%	25.6%
PAT	789	1,298
PAT %	11.1%	18.7%

R&D² INR 486 Cr | 6.8% of revenue

1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation

Highest-ever quarterly revenue of INR 3,452 Cr



Branded Prescription

- ❖ Cipla maintained #2 rank in overall chronic with chronic mix² improved to 60.4%
- ❖ Continued portfolio expansion with the launch of Yurpeak, Duolin Syncrobreathe, Doloneuron, and Nasowash
- ❖ Double-digit growth² in chronic therapies like Respiratory, Urology, Anti-diabetes and Cardiac




Trade Generics

- ❖ Posted steady growth supported by robust performance across key categories
- ❖ 4 Brands with TTM revenue of > INR 100 Cr and 3 Brands with TTM revenue of INR 50 Cr to INR 100 Cr
- ❖ 3 new launches in Q1FY27



Consumer Health

- ❖ Anchor and transitioned brands continuing to grow bigger
- ❖ Sustained EBITDA margin trajectory
- ❖ Nicotex, Omnigel and Cipladine maintained their leadership positions in the market



Largest pharma company by volume (units) in market¹

Our in-house brand franchise, Dyltor¹, has scaled to over INR 700 Cr+

Delivered market² growth of 15.4%, 183 bps higher than IPM

Key Market Highlights

1000+ Cr Foracort

Biggest Respiratory Brand in IPM¹

23 Brands

IPM¹ Brands in Top 300 ranks

33 Brands

IPM¹ Brands with revenue > INR 100 Cr

7 Therapies

With IPM¹ Top 5 ranks

Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies



Breath-actuated metered-dose inhaler used to manage and treat symptoms of COPD & Asthma



Neuro-pain brand with an extended-release offering aimed at improving adherence in chronic pain management



Supportive care brand with a differentiated combination of Hyaluronic Acid and N-Acetyl L-Cysteine



Oral JAK inhibitor for chronic inflammatory and autoimmune conditions



Upper-respiratory care brand with a saline-based nasal hygiene solution for congestion & dryness



Anti-allergy respiratory portfolio with Bilastine + Montelukast for allergic rhinitis and associated nasal symptoms



Neuro-supportive nutrition with a differentiated combination of PEA, Acetyl L-Carnitine, Boscurin and Uridine Monophosphate



Anti-diabetic brand in Type 2 diabetes, targeting improved glycaemic control

One India

prolyte™
ORS

Hydration

OMNIGEL®

Pain Relief

nicotex

Smoking
Cessation

CIPLADINE®

Skin Infection

cofsils

Cold and
Cough

Consumer Brands in
One India

Revenue : INR 481 Cr



Consumer Brands in
South Africa

Revenue : ZAR 405 Mn

One Africa

CORYX

Cold and
Cough

BRONCOL

Cold and
Cough

Cipla Actin

Respi OTC

IBUmax

Cold and Flu

ASTHAVENT
Metered-dose inhaler

Respi OTC

North America : Adapting to Evolving Business Dynamics

Key Business Highlights



- gProventil ranked No. 1 with total market¹ share at 21% (50 million+ inhaler units supplied to the U.S. market cumulatively)
- Launched gVentolin in the U.S. market during the quarter, with initial shipments executed and supply ramp-up planned over the coming quarters

Recent New Launches

gVentolin



Nintedanib



Dapagliflozin



Liraglutide




1. Market data as per IQVIA week ending 26th June'26 (No. 1 rank in overall U.S. Albuterol MDI market)

ANDA & NDA Portfolio & Pipeline (As on 30th June 2026)




■ Cipla Ltd ■ PEPFAR¹ ■ Invagen ■ Partnered ANDAs/NDAs



1. PEPFAR approved ANDAs can be commercialised in US

One Africa¹ : South Africa Private Growing Faster than the Market



SA Key Highlights²

- Healthy performance across key therapies like Respiratory, CNS and Alimentary TR & Metabolism.
- 10 brands with MAT market revenue > 100 Mn ZAR
- Highest number of brands in top 30 (6), top 50 (11) and top 100 (20) within generics segment
- Private business revenue of ZAR 906 Mn for Q1FY27

Market Segment ²	Rank	Share	Cipla Growth	Market Growth
South Africa Prescription	2	8.8%	9.8%	6.9%
South Africa OTC	3	7.8%	0.6%	3.5%
South Africa Overall	3	8.5%	6.5%	5.7%



Growth 1.2X
Faster growth than market for private business



4 new launches
Across multiple therapies in Q1 FY27

1. One Africa - South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT May'26

Progress on ESG goals (India Manufacturing Operations) : Q1FY27



Environment



Aspects	Goals FY 2029-30	Progress
Renewable Electricity Share	80% renewable electricity share for India manufacturing	57%*
GHG Emissions (Scope 1 & 2)	30% absolute reduction (Scope 1-Energy based & Scope-2) from baseline of FY2023-24 for Global Cipla Build capacity infrastructure for green propellants used in MDI	21% Ongoing pilot project
Water Neutrality	Water Neutral for India manufacturing	Achieved 2.6x water positivity FY26 Next Certification - Mar'27
Zero Waste to Landfill	Maintain ZWL status for Cipla India and expand coverage for ZWL to overseas sites for USA and One Africa	CMM Certified- July'26; India Manufacturing Certification - Mar'27
AMR	One antibiotic product per Cipla India site certified as per AMR manufacturing standard	Certification for 2 Sites - Mar'27
Occupational Health and Safety	Zero fatality in manufacturing operations	0
DEI	Representation of women in Cipla Leadership Group at 20% or above from a baseline year of FY25	14.8%
Responsible Procurement	Minimum 80% of critical Indian suppliers to comply with Cipla ESG framework	Preparation of supplier assessment ESG framework

Achievement

CIPLA MEDPRO MANUFACTURING PTY LTD, South Africa achieved the Green Building Council South Africa (GBCSA) Net Zero Waste Certification.

*With purchased I-RECs till Apr'26

Consolidated Profit and Loss Statement Summary

INR Cr

Particulars	Q1FY27	Q1FY26
Revenue from sale of products	7,077	6,837
Other operating income	42	120
Income from operations	7,119	6,957
Material cost	2,667	2,171
Employee benefits expense	1,497	1,312
Other expenses	1,762	1,696
Total expenses	5,927	5,179
Finance costs	17	14
Depreciation, impairment and amortisation expense	304	253
Other income	211	259
Profit before tax	1,082	1,770
Tax expenses	295	478
Share of associate	-2	-0
Profit for the period	786	1,292
Non-controlling interest	-3	-6
Profit for the period attributable to shareholders	789	1,298

Note : Figures have been rounded-off

Consolidated Balance Sheet



INR Cr

Key Balance Sheet Items	Jun-26	Jun-25
Equity	34,443	32,665
Total Debt [#]	600	459
Inventory	6,714	6,091
Cash and Cash Equivalents*	10,094	10,838
Trade Receivables	5,948	6,254
Trade Payables	3,446	3,093
Net Tangible Assets	7,889	6,669
Goodwill and Intangibles	6,928	5,138

[#]Total debt includes lease liabilities and borrowings | ^{*}Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances
| Figures have been rounded-off



Cipla

Thank You

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

Diksha Maheshwari

Investor.Relations@cipla.com

For more information, please visit

www.cipla.com